Brief: Oragenics Enters Into Material Transfer Agreement With Adjuvance Technologies For Covid-19 Vaccine Adjuvant
07/01/2021 12:10
Jan 7 (Reuters) - Oragenics Inc OGEN.A :
* ORAGENICS ENTERS INTO MATERIAL TRANSFER AGREEMENT WITH
ADJUVANCE
TECHNOLOGIES FOR COVID-19 VACCINE ADJUVANT
Source text for Eikon: ID:nBw1WDnRTa
Further company coverage: OGEN.A
((reuters.briefs@thomsonreuters.com;))
Recent news on Oragenics
See all newsBrief: Oragenics Reports Continued Clinical Progress, Provides Regulatory And NYSE American Listing Update
Brief: Oragenics Signs Letter Of Intent To License Cardiodialysis™ Technology From Sigyn Therapeutics To Target Tbi-Induced Systemic Inflammation
Brief: Oragenics Inc - Signs Letter Of Intent To License Cardiodialysis From Sigyn Therapeutics - SEC Filing
Brief: Oragenics Activates Second Site In Phase Iia Clinical Trial Of Onp-002 For Concussion And Mild Traumatic Brain Injury.
Brief: Oragenics Enters Settlement Agreement With Ladenburg Thalmann - Sec Filing